Netherlands, Utrecht


when 9 July 2012 - 13 July 2012
duration 1 week
fee EUR 1100

Today's society is confronted with ever increasing health care costs. One of the factors is the cost of drug innovations. Diseases waiting for therapeutic solutions, are complicated and multifactorial in nature. As a result, drug innovation has become even more complex leading to high tech and therefore high cost solutions. The question arises, what is the added value of such high cost innovations and how can it be determined when both benefit and harm are considered. Health economics, and more specifically pharmacoeconomics, aims to provide a neutral scientific approach to this challenge.
The course will cover these issues from a governmental, industry and regulatory perspective. All lecturers have extensive experience in the field and come from universities, regulatory bodies and pharmaceutical industry.

What to expect:

You will experience an intensive programme covering the following topics:
• Concepts in pharmacoeconomics
• Pharmacoeconomics & regulatory
• Orphan drugs
• Personalized medicine & pharmacoeconomics

Course leader

Dr. A.H.Maitland-van der Zee and Dr. A.M. Hövels

Target group

Postgraduates, clinicians and professionals within governments, industry, universities with a basic knowledge of epidemiology, pharmacoeconomics and an interest in benefit/risk evaluation of medicines.

Course aim

This course aims to provide a broad perspective of the field, including a variety of subjects from views of the different stakeholders to more in depth methodological approaches, illustrated with examples and exercises.

Credits info

Certificate of Attendance

Fee info

EUR 1100: Course + course materials + housing


Utrecht Summer School doesn't offer scholarships for this course.

Register for this course
on course website